cory_ATX — that is really helpful context on Semaglutide liver fat. Follow-up question: what labs did your doctor order to monitor this?
I am in a similar situation (just started) and trying to set realistic expectations.
To answer HealthEcon_DC's question specifically:
From a clinical standpoint, Semaglutide liver fat is an area where we have good evidence.
The short answer: baseline labs + quarterly monitoring is the standard of care.
The longer answer involves understanding the mechanism of action at the receptor level, which I am happy to elaborate on if helpful.
Thank you kevin_tulsa! This is incredibly helpful. Bookmarking for later. 🙏
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemRelevant to Semaglutide liver fat — here is my latest bloodwork comparison:
Key improvements: A1C 8.4% → 5.5%, triglycerides 205 → 105 mg/dL, hsCRP 8.0 → 1.1 mg/L. All on tirzepatide for 9 months.
The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.
Slightly tangential to Semaglutide liver fat but kevin_tulsa reminded me — what is the latest on the oral formulations?
I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.